Skin Structures and Soft Tissue Infections Clinical Trial
Official title:
A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
This is a multicenter, randomized, double-blind study of the efficacy and safety of IV iclaprim compared to IV vancomycin. Patients will receive either iclaprim or vancomycin for 5 to 14 days. Patients will be evaluated daily up to early time point (ETP), then every 48 to 72 hours through the end of treatment. Patients will also be evaluated at the test of cure (TOC) visit (7 to 14 days post-EOT), and will have a Late Follow-Up (LFU) visit (28 to 32 days post-first dose). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02600611 -
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
|
Phase 3 | |
| Completed |
NCT01984684 -
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
|
Phase 3 | |
| Completed |
NCT02378480 -
Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
|
Phase 3 | |
| Withdrawn |
NCT00876850 -
Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
|
Phase 3 | |
| Completed |
NCT02863874 -
The PLUS Study: Comparison of VicrylPlus® Versus Vicryl® for Repair of Perineal Tears
|
N/A | |
| Completed |
NCT02877927 -
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
|
Phase 3 |